Merck & Co., known as MSD outside the US, has agreed to buy ArQule for $20 per share, bringing with it the BTK inhibitor ARQ 531. Massachusetts-based ArQule’s lead candidate, ARQ 531 is a novel ...

Merck's pipeline includes a number of drug candidates in clinical trials for haematological malignancies, including BTK inhibitor nemtabrutinib (MK-1026), anti-LAG-3 antibody favelizumab (MK-4280 ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was approved by the FDA in 2015 to reverse the anesthesia-induced neuromuscular ...

This week, the European Commission (“EC”) granted approval to Merck’s MRK Keytruda in ... a phase III study on its investigational oral BTK inhibitor, tolebrutinib. Eli Lilly LLY announced ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor ...

The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.

Researchers determined discontinuing BTK inhibitors appears to be more common than discontinuing venetoclax plus obinutuzumab for older patients with CLL.